Arcutis (ARQT) | Financial Analysis & Statements
Arcutis Biotherapeutics Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
129.5M
Gross Profit
117.8M
90.97%
Operating Income
18.4M
14.20%
Net Income
17.4M
13.43%
Balance Sheet Metrics
Total Assets
433.0M
Total Liabilities
243.5M
Shareholders Equity
189.5M
Debt to Equity
1.29
Cash Flow Metrics
Operating Cash Flow
4.0M
Free Cash Flow
26.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Arcutis Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 376.1M | 196.5M | 59.6M | 3.7M | 0 |
| Cost of Goods Sold | 36.7M | 19.1M | 5.0M | 754.0K | 0 |
| Gross Profit | 339.4M | 177.4M | 54.6M | 2.9M | 0 |
| Gross Margin % | 90.2% | 90.3% | 91.6% | 79.5% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 77.1M | 76.4M | 110.6M | 182.4M | 145.6M |
| Selling, General & Administrative | 274.6M | 229.4M | 185.1M | 122.1M | 61.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 351.6M | 305.8M | 295.7M | 304.6M | 206.5M |
| Operating Income | -12.2M | -128.4M | -241.1M | -301.6M | -206.5M |
| Operating Margin % | -3.3% | -65.3% | -404.5% | -8,183.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 8.9M | - | - | - | - |
| Interest Expense | 12.1M | 27.2M | 29.7M | 15.7M | 0 |
| Other Non-Operating Income | 443.0K | 16.2M | 11.8M | 5.8M | 173.0K |
| Pre-tax Income | -15.0M | -139.4M | -259.0M | -311.5M | -206.4M |
| Income Tax | 1.2M | 647.0K | 3.1M | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -16.1M | -140.0M | -262.1M | -311.5M | -206.4M |
| Net Margin % | -4.3% | -71.3% | -439.8% | -8,449.8% | 0.0% |
| Key Metrics | |||||
| EBITDA | 1.8M | -109.6M | -227.8M | -294.9M | -205.9M |
| EPS (Basic) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 |
| EPS (Diluted) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 |
| Basic Shares Outstanding | 127234000 | 120957633 | 69305487 | 55032265 | 49405575 |
| Diluted Shares Outstanding | 127234000 | 120957633 | 69305487 | 55032265 | 49405575 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Arcutis Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 42.9M | 71.3M | 88.4M | 53.6M | 96.4M |
| Short-term Investments | 178.1M | 156.6M | 183.5M | 355.9M | 290.6M |
| Accounts Receivable | 146.2M | 73.1M | 25.8M | 8.5M | 0 |
| Inventory | 22.6M | 14.5M | 13.1M | 7.5M | 0 |
| Other Current Assets | 9.0M | 8.2M | 8.2M | 6.3M | 8.0M |
| Total Current Assets | 411.2M | 335.8M | 330.4M | 437.4M | 402.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 4.5M | 2.0M | 2.4M | 2.7M | 3.0M |
| Goodwill | 14.8M | 9.5M | 6.4M | 7.2M | 0 |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.4M | 596.0K | 596.0K | 78.0K | 78.0K |
| Total Non-Current Assets | 21.7M | 13.1M | 10.9M | 11.9M | 5.4M |
| Total Assets | 433.0M | 348.9M | 341.4M | 449.3M | 408.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 12.5M | 14.2M | 12.0M | 8.8M | 7.4M |
| Short-term Debt | 1.0M | 820.0K | 735.0K | 657.0K | 433.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 129.8M | 81.0M | 46.7M | 37.8M | 33.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 113.2M | 109.8M | 205.2M | 201.9M | 77.1M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 431.0K | 570.0K | 849.0K | - | 25.0K |
| Total Non-Current Liabilities | 113.7M | 110.3M | 206.0M | 201.9M | 77.1M |
| Total Liabilities | 243.5M | 191.3M | 252.7M | 239.7M | 110.5M |
| Equity | |||||
| Common Stock | 12.0K | 12.0K | 9.0K | 6.0K | 5.0K |
| Retained Earnings | -1.1B | -1.1B | -981.9M | -719.8M | -408.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 189.5M | 157.5M | 88.7M | 209.6M | 297.7M |
| Key Metrics | |||||
| Total Debt | 114.2M | 110.6M | 205.9M | 202.5M | 77.6M |
| Working Capital | 281.4M | 254.8M | 283.8M | 399.6M | 369.4M |
Balance Sheet Composition
Arcutis Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -16.1M | -140.0M | -262.1M | -311.5M | -206.4M |
| Depreciation & Amortization | 4.7M | 2.6M | 1.5M | 934.0K | 454.0K |
| Stock-Based Compensation | 40.4M | 41.7M | 38.8M | 32.7M | 23.9M |
| Working Capital Changes | -82.9M | -46.2M | -20.5M | -14.8M | 488.0K |
| Operating Cash Flow | -51.6M | -136.1M | -237.9M | -260.1M | -181.2M |
| Investing Activities | |||||
| Capital Expenditures | -686.0K | -143.0K | -428.0K | -333.0K | -995.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -247.0M | -254.8M | -225.8M | -415.4M | -292.5M |
| Investment Sales | 227.4M | 288.8M | 406.5M | 351.5M | 217.6M |
| Investing Cash Flow | -20.3M | 33.8M | 180.2M | -64.2M | -76.0M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 0 | 0 | 125.0M | 74.0M |
| Debt Repayment | 0 | -100.0M | - | - | - |
| Financing Cash Flow | 0 | 61.7M | 98.9M | 298.9M | 279.8M |
| Free Cash Flow | -16.3M | -117.3M | -247.5M | -281.0M | -175.6M |
| Net Change in Cash | -71.8M | -40.6M | 41.2M | -25.5M | 22.7M |
Cash Flow Trend
Arcutis Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-179.00
Forward P/E
19.29
Price to Book
15.14
Price to Sales
7.74
PEG Ratio
0.70
Profitability Ratios
Profit Margin
-4.29%
Operating Margin
14.20%
Return on Equity
-9.30%
Return on Assets
-1.96%
Financial Health
Current Ratio
3.17
Debt to Equity
60.44
Beta
1.77
Per Share Data
EPS (TTM)
$-0.13
Book Value per Share
$1.54
Revenue per Share
$2.96
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ARQT | 2.9B | -179.00 | 15.14 | -9.30% | -4.29% | 60.44 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






